通过尿道下腔注射安全提供 ICI 治疗

IF 12.1 1区 医学 Q1 UROLOGY & NEPHROLOGY
Maria Chiara Masone
{"title":"通过尿道下腔注射安全提供 ICI 治疗","authors":"Maria Chiara Masone","doi":"10.1038/s41585-024-00884-w","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19088,"journal":{"name":"Nature Reviews Urology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safe delivery of ICI therapy through sub-urothelial injection\",\"authors\":\"Maria Chiara Masone\",\"doi\":\"10.1038/s41585-024-00884-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19088,\"journal\":{\"name\":\"Nature Reviews Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":12.1000,\"publicationDate\":\"2024-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41585-024-00884-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Urology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41585-024-00884-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

人类单克隆抗 PDL1 抗体 durvalumab 的全身治疗对多种癌症都有疗效。在《国际泌尿外科杂志》(BJU International)发表的一项 Ib 期研究中,对计划接受根治性膀胱切除术的非转移性肌浸润性或非肌浸润性膀胱癌患者进行了尿道下注射 durvalumab 的安全性评估。共有11名患者接受了尿道下注射durvalumab,剂量分别为25、75和150毫克。报告的不良事件(AE)大多为1级和2级。唯一观察到的3级不良反应与德瓦鲁单抗治疗无关,也未报告4级或5级不良反应。在接受度伐卢单抗治疗后,组织免疫群体(研究的次要终点)发生了变化,M2-巨噬细胞(CD163)增加,表明出现了局部免疫反应。这些结果鼓励开展进一步研究,评估通过这种局部方式进行免疫疗法的疗效,从而避免与全身治疗相关的不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safe delivery of ICI therapy through sub-urothelial injection
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Nature Reviews Urology
Nature Reviews Urology 医学-泌尿学与肾脏学
CiteScore
12.50
自引率
2.60%
发文量
123
审稿时长
6-12 weeks
期刊介绍: Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信